Why the Pro Medicus Limited share price has been soaring higher

Pro Medicus Limited (ASX:PME) has nearly tripled in value in 2015.

| More on:
a woman

One of the best-performing small-cap stocks over the past couple of months is medical imaging software retailer Pro Medicus Limited (ASX: PME).

The company has nearly tripled in value over the course of 2015 thanks to growing sales of its software that lets radiologists view images on mobile or desktop platforms.

The different software packages it sells also helps its healthcare clients improve efficiency in terms of record keeping, reporting, patient management and administration.

Unsurprisingly much of Pro Medicus’s success has been in the world’s largest private healthcare market of the US, where the opportunity to save on costs and lift profit is constantly sought after by a network of private hospitals, insurers, and private imaging centres.

The company posted a profit of $3.2 million on revenues of $17.6 million for the financial year ending June 2015. The group’s current market valuation of $335 million looks lofty in the context of its most recent financial results, although it has made a very strong start to this financial year with several big new client wins in the US.

One deal announced last month was worth $11 million over a five-year period and as a software-oriented business it has plenty of operating leverage to increase profits faster than revenues as the cost base is relatively fixed. Pro Medicus is also founder led and has potential for margin and geographic market expansion.

Given that for now much of the revenues are earned in the US the outlook for the Australian dollar is another consideration and its recent weakening has proven another tailwind.

The market is clearly expecting more growth to come from the US market and with momentum and technology on its side Pro Medicus may keep delivering yet.

Other junior medical device businesses performing well recently include sleep treatment innovator Somnomed Limited (ASX: SOM) and medical device disinfectant specialist Nanosonics Ltd. (ASX: NAN). Both of these businesses are also succeeding in growing sales in the US private healthcare market and are worth considering for investors prepared to take on more risk.

Wondering where you should invest $1,000 right now?

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes could be the five best ASX stocks for investors to buy right now. These stocks are trading at near dirt-cheap prices and Scott thinks they could be great buys right now.

*Returns as of August 16th 2021

Motley Fool contributor Tom Richardson has no position in any stocks mentioned. Unless otherwise noted, the author does not have a position in any stocks mentioned by the author in the comments below. The Motley Fool Australia has no position in any of the stocks mentioned. You can find Tom on Twitter @tommyr345 We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on ⏸️ Investing